Lurasidone-d8-1 (hydrochloride)

• UNSPSC Description:

  Lurasidone-d8-1 (hydrochloride) is deuterium labeled Lurasidone (Hydrochloride). Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is an antagonist of both dopamine D2 and 5-HT7 with IC50s of 1.68 and 0.495 nM, respectively. Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is also a partial agonist of 5-HT1A receptor with an IC50 of 6.75 nM[1].

• Target Antigen:

  5-HT Receptor; Dopamine Receptor; Isotope-Labeled Compounds

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling;Others

• Field of Research:

  Neurological Disease

• Smiles:

  [H][C@]12C[C@@]([H])(CC2)[C@@]3([H])[C@]1([H])C(N(C3=O)C[C@@H]4CCCC[C@H]4CN5C([2H])(C([2H])(N(C([2H])(C5([2H])[2H])[2H])C6=NSC7=C6C=CC=C7)[2H])[2H])=O.Cl

• Molecular Weight:

  537.19

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Sakine Atila Karaca, et al. Development of a validated high-performance liquid chromatographic method for the determination of Lurasidone in pharmaceuticals. Marmara Pharm J. 2017;21 (4): 931-937.|[3]Ishibashi T, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010 Jul;334(1):171-81.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported